The Rationale for the Phase I TRANSCEND NHL 001 Trial
Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the rationale for phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory large B-cell lymphoma, which were presented at the 2019 American Society of Hematology Annual Meeting.
TRANSCEND-NHL 001 was launched to serve an unmet medical need for new treatment options in this patient population. Conventional therapies have a low single-agent response rate, no chance of cure, and median overall survival of 6 month or less in these patient. The hope was that liso-cel would improve outcomes and quality of life in these patients, says Abramson.
For more about the TRANCEND-NHL 001 trialhttps://www.targetedonc.com/news/fda-grant-priority-review-to-lisocel-in-relapsedrefractory-large-bcell-lymphoma
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
